FDA mon­i­tor­ing 20 drugs at risk of short­age due to coro­n­avirus

As part of its ef­forts to en­sure the sup­ply of med­ical prod­ucts from Chi­na dur­ing the on­go­ing coro­n­avirus (Covid-19) out­break, the FDA has iden­ti­fied 20 drugs that are made in or pro­duced sole­ly from ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs) sourced from Chi­na.

In a state­ment to Fo­cus, FDA spokesper­son Stephanie Cac­co­mo said the agency has been in con­tact with the com­pa­nies that make the 20 prod­ucts and that “none of these firms has re­port­ed any short­age to date.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.